Stay updated on Comparing Lenvatinib vs Sorafenib in Hepatocellular Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Comparing Lenvatinib vs Sorafenib in Hepatocellular Carcinoma Clinical Trial page.

Latest updates to the Comparing Lenvatinib vs Sorafenib in Hepatocellular Carcinoma Clinical Trial page
- Check6 days agoChange DetectedThe page’s footer “Revision” version has been updated from v3.5.2 to v3.5.3, indicating a website release/version change rather than an update to the clinical trial information.SummaryDifference0.0%

- Check13 days agoChange DetectedRevision: v3.5.2 was added and Revision: v3.5.0 was removed.SummaryDifference0.0%

- Check20 days agoChange DetectedNo substantive changes to the page content were detected. The study overview, design, eligibility criteria, and outcomes remain as shown.SummaryDifference0.0%

- Check35 days agoChange DetectedNaples, Italy has been added as a location. Napoli, Italy has been removed.SummaryDifference0.0%

- Check42 days agoChange DetectedAdded Hepatocellular carcinoma as a study topic and linked the Genetic and Rare Diseases Information Center as a resources reference. Updated the site revision from v3.4.3 to v3.5.0.SummaryDifference0.1%

- Check49 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3 on the page.SummaryDifference0.0%

Stay in the know with updates to Comparing Lenvatinib vs Sorafenib in Hepatocellular Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Comparing Lenvatinib vs Sorafenib in Hepatocellular Carcinoma Clinical Trial page.